NCT05768230 is a Phase 2, PHASE3 clinical trial of levosimendan in Transesophageal Echocardiography, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT05768230?

Interventions in NCT05768230: levosimendan, 5% glucose injection.

What condition does NCT05768230 study?

NCT05768230 studies Transesophageal Echocardiography, Acute Respiratory Distress Syndrome, Right Ventricular Dysfunction.

Is NCT05768230 still recruiting?

NCT05768230 is currently status unknown. Last updated 14 March 2023.

Last reviewed 2023-03-14 · How we verify

NCT05768230

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV

Status unknown Phase 2, PHASE3 Last updated 14 March 2023

What this trial tests

Phase 2, PHASE3 trial testing levosimendan in Transesophageal Echocardiography in 58 participants. Status unknown.

Timeline

22 March 2023

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	58
Start date	22 March 2023
Primary completion	1 December 2025
Estimated completion	1 December 2025
Sites	1 location across China

Drugs / interventions tested

levosimendan (LEVOSIMENDAN) — full drug profile →
5% glucose injection — full drug profile →

Conditions studied

Transesophageal Echocardiography — all drugs for Transesophageal Echocardiography →
Acute Respiratory Distress Syndrome — all drugs for Acute Respiratory Distress Syndrome →
Right Ventricular Dysfunction — all drugs for Right Ventricular Dysfunction →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 80, any sex, with Transesophageal Echocardiography or Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute respiratory distress syndrome (ARDS) is often complicated by right ventricular dysfunction (RVD), Acute cor pulmonale is the most serious form of ARDS complicated with RVD.Levosimendan is indicated for short-term treatment of acute decompensated heart failure that is not responding well to conventional therapy and requires increased myocardial contractile force.In 2016, the European Society of Cardiology issued recommendations for the management of acute right heart failure, stating that levosimendan can improve right ventriculo-pulmonary artery coupling by both increasing right heart contractility and reducing pulmonary vascular resistance.However, the clinical application of levosimendan in the treatment of ARDS right heart dysfunction is insufficient.Therefore, this study intends to use transesophageal ultrasound to evaluate right ventricular function, reduce the limitation of poor right ventricular window in transthoracic echocardiography, and conduct a multi-center randomized controlled study to further explore the effects of levosimendan on right ventricular function in ARDS patients, such as tricuspid ring systolic displacement (TAPSE) and tricuspid ring systolic displacement velocity (S '). Effects of right ventricular area change fraction (RV FAC), right ventricular end-diastolic area/left ventricular end-diastolic area (RVEDA/LVEDA), pulmonary circulation resistance (PVR), hemodynamics and mortality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of levosimendan

Trials testing the same drug.

NCT07105202 — Shorter Weaning From Invasive Ventilation With Levosimendan · Phase 4 · recruiting
NCT04950569 — Effect of Levosimendan on miRNAs Regulation in the Failing Hearts · Phase 4 · unknown
NCT01500785 — Intracoronary Administration of Levosimendan in Cardiac Surgery Patients · Phase 4 · terminated

Other recruiting trials for Transesophageal Echocardiography

Currently open trials in the same condition.

NCT07496424 — Manual- VS Auto-Strain · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05768230 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 14 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05768230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing